• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.

    1/5/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care
    Get the next $BLCO alert in real time by email
    • Bausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research
    • Bausch + Lomb will also sponsor The Glaucoma Foundation's annual month-long educational social media campaign, which spotlights stories from glaucoma patients and advocates
    • Glaucoma affects about four million people in the United States1

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, is launching its fifth annual fundraising challenge with Glaucoma Research Foundation (GRF) during Glaucoma Awareness Month in January. Bausch + Lomb will also sponsor The Glaucoma Foundation's (TGF) social media campaign to raise awareness of the disease and its impact by highlighting a glaucoma patient or advocate every day in January.

    "Currently, about four million people in the United States are affected by glaucoma, and this number is only expected to grow as the population ages," said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. "Our collaborations with GRF and TGF will advance education and research efforts designed to improve the lives of those affected by glaucoma and encourage everyone to be proactive when it comes to eye health."

    As part of the fundraising challenge with GRF, Bausch + Lomb will match every dollar raised during January, up to $20,000. All proceeds will support critical research for glaucoma, a leading cause of irreversible blindness in the U.S.1

    "Glaucoma often progresses without noticeable symptoms, making research and improved education vital to saving sight," said Thomas M. Brunner, president and CEO, Glaucoma Research Foundation. "Our continued partnership with Bausch + Lomb supports our efforts to accelerate the discoveries that can make a real difference for people living with this disease."

    Learn more about GRF or make a donation at www.glaucoma.org.

    TGF's social media campaign aims to put a human face to the disease, raise awareness and stress the importance of early detection by sharing personal stories from a patient or advocate each day during the month of January.

    "Due to the chronic, progressive nature of glaucoma, early intervention can mean the difference between saving and losing sight," said Elena Sturman, president and CEO, The Glaucoma Foundation. "In partnership with Bausch + Lomb, our campaign will showcase real-world experiences with glaucoma, create greater awareness and bring hope to those affected by this disease."

    Learn more about The Glaucoma Foundation at www.glaucomafoundation.org and follow the organization on Facebook, Instagram, LinkedIn and X to experience the social media campaign throughout Glaucoma Awareness Month.

    About Glaucoma

    Glaucoma is a chronic, progressive disease that occurs when excessive eye pressure or other causes lead to damage of the optic nerve. The optic nerve is responsible for the communication of information between the eye and brain. Damage to the optic nerve can lead to severe vision loss, and in the worst case, blindness. As the leading cause of irreversible blindness, glaucoma affects about four million people in the United States, but if caught early, it is possible to help slow and potentially prevent vision loss.1-3

    About Bausch + Lomb

    Our mission is simple – we help people see better to live better, all over the world. For nearly two centuries we've evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we're turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com and connect with us on Facebook, Instagram, LinkedIn, X and YouTube.

    About Glaucoma Research Foundation

    Glaucoma Research Foundation (GRF) is a national non-profit organization dedicated to finding a cure for glaucoma. GRF funds glaucoma research worldwide and serves as the leading information source for patients and their families. Founded in 1978 in San Francisco, GRF was created to encourage innovative research to find better ways to care for people with glaucoma — the leading cause of preventable blindness. Since its inception, GRF has invested more than $90 million to fund breakthrough research to better understand, detect, and treat glaucoma.

    About The Glaucoma Foundation

    Since 1984, The Glaucoma Foundation has worked to identify, encourage, and fund scientific research into the potentially blinding disease of glaucoma, with the goal of eradicating vision loss and blindness from glaucoma. Through education and outreach, we strive to be a valuable resource to improve the lives of those affected by the disease.

    References

    1. Ehrlich JR, Burke-Conte Z, Wittenborn JS, et al. Prevalence of Glaucoma Among US Adults in 2022. JAMA Ophthalmol. 2024;142(11):1046–1053. doi:10.1001/jamaophthalmol.2024.3884
    2. John Hopkins. Glaucoma. Retrieved from https://www.hopkinsmedicine.org/health/conditions-and-diseases/glaucoma. Reviewed on Nov. 7, 2025.
    3. National Eye Institute. Glaucoma and Eye Pressure. Retrieved from https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/glaucoma/glaucoma-and-eye-pressure. Reviewed on Nov. 7, 2025.

    © 2025 Bausch + Lomb.

    BLNP.0137.USA.25

    View source version on businesswire.com: https://www.businesswire.com/news/home/20260105643250/en/

    Bausch + Lomb Media Contact

    Caryn Marshall

    [email protected]

    (908) 493-1381

    Glaucoma Research Foundation Media Contact:

    Andrew J. Jackson

    [email protected]

    (415) 986-3162

    The Glaucoma Foundation Media Contact:

    Gabrielle Bamberger

    [email protected]

    917-273-7382

    Get the next $BLCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLCO

    DatePrice TargetRatingAnalyst
    1/5/2026$18.00Outperform → In-line
    Evercore ISI
    12/11/2025$20.00Neutral → Buy
    Citigroup
    12/2/2025$21.00Equal-Weight → Overweight
    Morgan Stanley
    10/1/2025$16.00Neutral
    Goldman
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $BLCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bausch + Lomb downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $18.00

    1/5/26 8:46:17 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Citigroup with a new price target

    Citigroup upgraded Bausch + Lomb from Neutral to Buy and set a new price target of $20.00

    12/11/25 8:44:49 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $21.00

    12/2/25 8:17:09 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    SEC Filings

    View All

    SEC Form 10-K filed by Bausch + Lomb Corporation

    10-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 5:19:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    2/18/26 7:01:45 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits

    8-K - Bausch & Lomb Corp (0001860742) (Filer)

    1/2/26 4:10:34 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bausch + Lomb Launches R&D "Teach-in" Webinar Series

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will provide deeper insights on the company's differentiated product pipeline, which was unveiled in November 2025. On Monday, March 23, 2026, at 1:30 p.m. ET, Executive Vice President of Research & Development and Chief Medical Officer Yehia Hashad, MD, will be joined by members of his leadership team to discuss two glaucoma assets: BL1107, a glaucoma medication under development that would be the first to treat vision loss in addition to lowering intraocular pressure ELIOS™, an

    3/9/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Ophthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®

    Global review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever eye drops (brimonidine tartrate 0.025%) are highlighted as a differentiated OTC option due to its highly selective α2 mechanism, with no tachyphylaxis over 29 days and virtually no rebound redness Review also notes a preservative-free formulation of brimonidine tartrate 0.025% showing comparable efficacy, safety and tolerability; Bausch + Lomb introduced LUMIFY Preservative Free Eye Drops in 2025 Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping peop

    2/24/26 7:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bausch + Lomb Corporation

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 5:23:22 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and CFO Eldessouky Sam bought $68,520 worth of shares (4,000 units at $17.13) and was granted 4,000 shares, increasing direct ownership by 2% to 407,130 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:34:11 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    CEO and Chairman of the Board Saunders Brent L bought $251,958 worth of shares (14,700 units at $17.14) and was granted 14,700 shares, increasing direct ownership by 3% to 981,275 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/10/26 4:32:06 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Director Ross Thomas W. Sr. bought $79,556 worth of shares (4,500 units at $17.68) and was granted 4,500 shares, increasing direct ownership by 15% to 69,391 units (SEC Form 4)

    4 - Bausch & Lomb Corp (0001860742) (Issuer)

    3/4/26 4:18:54 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Leadership Updates

    Live Leadership Updates

    View All

    Bausch + Lomb Announces 2025 Annual Meeting of Shareholders Results

    Bausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2025 Annual Meeting of Shareholders (the "Annual Meeting") held on May 21, 2025. Detailed results of the vote follow: Name For   Against   Broker Non-Votes Nathalie Bernier   337,617,248   1,924,336   8,383,437 Gary Hu   337,591,706   1,949,878   8,383,437 Brett Icahn   337,474,287   2,067,297   8,383,437 Sarah B. Kavanagh   337,602,211   1,939,373  

    5/21/25 4:30:00 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

    Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

    2/28/24 8:00:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

    2/21/24 7:00:00 AM ET
    $BLCO
    $EBS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BLCO
    Financials

    Live finance-specific insights

    View All

    Bausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 Guidance

    Delivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $58 Million Adjusted EBITDA (non-GAAP)1 of $326 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $330 Million Revenue Grew 10% as Reported and 7% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2024 Full-Year 2025 Financial Results Revenue of $5.101 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $360 Million Adjusted EBITDA (non-GAAP)1 of $858 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1

    2/18/26 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18

    Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2025 financial results on Wednesday, Feb. 18, 2026. The company will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, Feb. 18, 2026   Time: 8:00 a.m. ET   Webcast: https://www.webcaster5.com/Webcast/Page/2883/53392   Pa

    1/20/26 7:15:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Announces Third-Quarter 2025 Results

    Revenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243 Million Revenue Grew 7% as Reported and 6% on a Constant Currency1 Basis Compared to the Third Quarter of 2024 Updating Full-Year 2025 Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2025 financial results. "We're delivering on the vision we laid out in 2023, with a base business engine that con

    10/29/25 6:58:00 AM ET
    $BLCO
    Ophthalmic Goods
    Health Care

    $BLCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bausch + Lomb Corporation

    SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

    2/14/23 5:14:30 PM ET
    $BLCO
    Ophthalmic Goods
    Health Care